Chugai Pharmaceutical Co., Ltd. (4519)

Currency in JPY
6,270.0
-30.0(-0.48%)
Closed·
4519 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
4519 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6,231.06,313.0
52 wk Range
5,942.08,655.0
Key Statistics
Bid/Ask
6,269.00 / 6,271.00
Prev. Close
6,300
Open
6,309
Day's Range
6,231-6,313
52 wk Range
5,942-8,655
Volume
3.14M
Average Volume (3m)
2.72M
1-Year Change
-8.51%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4519 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
8,121.4
Upside
+29.53%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 4 consecutive years
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Chugai Pharmaceutical Co., Ltd. Company Profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. Chugai Pharmaceutical Co., Ltd. was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Employees
5026
Market
Japan

Compare 4519 to Peers and Sector

Metrics to compare
4519
Peers
Sector
Relationship
P/E Ratio
26.2x17.5x−0.6x
PEG Ratio
2.310.130.00
Price/Book
5.2x1.6x2.6x
Price / LTM Sales
8.7x1.6x3.3x
Upside (Analyst Target)
34.1%−0.3%40.0%
Fair Value Upside
Unlock15.2%4.7%Unlock

Analyst Ratings

7 Buy
6 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 8,121.4
(+29.53% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 240.31%
Dividend Yield
3.97%
Industry Median 2.52%
Annualised payout
250.00
Paid unevenly
5-Years Growth
+21.15%
Growth Streak

Earnings

Latest Release
Jul 24, 2025
EPS / Forecast
57.83 / 73.49
Revenue / Forecast
290.00B / 316.29B
EPS Revisions
Last 90 days

4519 Income Statement

People Also Watch

20,095.0
8035
-1.59%
4,124.0
6501
+0.44%
2,291.0
8306
+1.62%
10,765.0
6857
-1.64%

FAQ

What Stock Exchange Does Chugai Pharmaceutical Trade On?

Chugai Pharmaceutical is listed and trades on the Tokyo Stock Exchange stock exchange.

What Is the Stock Symbol for Chugai Pharmaceutical?

The stock symbol for Chugai Pharmaceutical is "4519."

What Is the Chugai Pharmaceutical Market Cap?

As of today, Chugai Pharmaceutical market cap is 10.30T.

What Is Chugai Pharmaceutical's Earnings Per Share (TTM)?

The Chugai Pharmaceutical EPS (TTM) is 240.31.

When Is the Next Chugai Pharmaceutical Earnings Date?

Chugai Pharmaceutical will release its next earnings report on 23 Oct 2025.

From a Technical Analysis Perspective, Is 4519 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Chugai Pharmaceutical Stock Split?

Chugai Pharmaceutical has split 3 times.

How Many Employees Does Chugai Pharmaceutical Have?

Chugai Pharmaceutical has 5026 employees.

What is the current trading status of Chugai Pharmaceutical (4519)?

As of 22 Aug 2025, Chugai Pharmaceutical (4519) is trading at a price of 6,270.00, with a previous close of 6,300.00. The stock has fluctuated within a day range of 6,231.00 to 6,313.00, while its 52-week range spans from 5,942.00 to 8,655.00.

What Is Chugai Pharmaceutical (4519) Price Target According to Analysts?

The average 12-month price target for Chugai Pharmaceutical is JPY8121.42857, with a high estimate of JPY10800 and a low estimate of JPY6100. 7 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +29.53% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.